The Living Guidelines: UA/NSTEMI Recomendations for PCI View the Current CLASS I Guidelines
- Class I
1. An early invasive PCI strategy is indicated for patients with UA/ NSTEMI who have no serious comorbidity and who have coronary lesions amenable to PCI and any of the high-risk features listed in Section 3.3. (See Section 3.3 for specific recommendations and their Level of Evidence.)
2. Percutaneous coronary intervention (or CABG) is recommended for UA/NSTEMI patients with 1- or 2-vessel CAD with or without significant proximal left anterior descending CAD but with a large area of viable myocardium and high-risk criteria on noninvasive testing. (Level of Evidence: B)
3. Percutaneous coronary intervention (or CABG) is recommended for UA/NSTEMI patients with multivessel coronary disease with suitable coronary anatomy, with normal LV function, and without diabetes mellitus. (Level of Evidence: A)
4. An intravenous platelet GP IIb/IIIa inhibitor is generally recommended in UA/NSTEMI patients undergoing PCI. (Level of Evidence: A) See UA/STEMI Guidelines 2007, Section 3.2.3 and Figures 7, 8, and 9 for details on timing and dosing recommendations (see UA/STEMI Guidelines 2007, Table 13).